<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jacobson, Anne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Sever, Peter S.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ASCOT-LLA: Statin Legacy Felt with Reduced Non-CV Death Eight Years after Trial End?</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">22-23</style></pages><abstract><style  face="normal" font="default" size="100%">Prior treatment with atorvastatin is associated with a reduction in the risk of all-cause mortality compared with placebo 8 years after the early termination of the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm [ASCOT-LLA] and 11 years after initial randomization, according to new findings from a long-term follow-up study.</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>